Section Arrow
MAZE.NASDAQ
- Maze Therapeutics Inc
Quotes are at least 15-min delayed:2025/12/22 18:28 EST
After Hours
Last
 41.98
0 (0.00%)
Bid
41.91
Ask
41.98
High 42.81 
Low 41.98 
Volume 82.17K 
Regular Hours (Closed)
Last
 41.98
+0.27 (+0.65%)
Day High 
42.69 
Prev. Close
41.71 
1-M High
43.29 
Volume 
390.15K 
Bid
41.91
Ask
41.98
Day Low
41.3472 
Open
41.71 
1-M Low
34.44 
Market Cap 
2.01B 
Currency 美元 
P/E 191.34 
%Yield -- 
10-SMA 40.01 
20-SMA 39.3 
50-SMA 34.34 
52-W High 43.29 
52-W Low 6.71 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.56/-3.00
Enterprise Value
2.03B
Balance Sheet
Book Value Per Share
7.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
167.50M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
FOLDAmicus Therapeutics14.21+0.03+0.21%-- 
After Hours 14.19 -0.02 -0.14%
RXRXRecursion Pharmaceuticals4.4+0.14+3.29%-- 
After Hours 4.39 -0.01 -0.23%
MENSJyong Biotech Ltd4.78+1.605+50.55%-- 
After Hours 4.65 -0.13 -2.72%
IOVAIovance Biotherapeutics2.78+0.3+12.10%-- 
After Hours 2.79 +0.01 +0.36%
IBRXImmunityBio2.27+0.19+9.13%-- 
After Hours 2.2701 +0.0001 0.00%
Industry overview quotes are at least 15 minutes delayed
Business Description
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.